CN Mobile Logo

Search form



The Role of Intralesional Therapies in Melanoma

Sanjiv S. Agarwala, MD
Through the emergence of new immunotherapies, treatment of melanoma is undergoing a long-awaited revolution. Ongoing research will clarify the outlines of the place that intralesional therapies will occupy in the therapeutic armamentarium in the years ahead.


Updated efficacy results of the coBRIM trial showed that cobimetinib plus vemurafenib improved survival in patients with BRAF V600–mutated advanced melanoma.

There is currently not enough evidence to assess the balance of benefits and harms of a visual skin examination by a clinician to screen for skin cancer in asymptomatic adults.

In this interview we discuss a recent study that identified genetic mechanisms of immunoresistance to treatment with anti-PD-1 antibodies.

In this video we discuss the use of concurrent immunotherapy and stereotactic radiosurgery for treatment of melanoma brain metastases.

Undergoing immunotherapy within a month of stereotactic radiosurgery resulted in an improved response to treatment for patients with melanoma brain metastases.

In this video we discuss 3-year results of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma.

In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.


Subscribe to Melanoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.